Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a clinical-stage biotechnology company headquartered in New York, NY, focused on developing novel therapies for diseases of the central nervous system (CNS). The company's lead product candidate, REL-1017 (esmethadone), is a proprietary D-isomer of racemic methadone being developed as a treatment for major depressive disorder (MDD) and potentially other CNS indications, including Alzheimer's disease-associated depression and neuropathic pain[1].
Unlike traditional antidepressants, REL-1017 acts through a unique dual mechanism involving NMDA receptor modulation and sigma-1 receptor agonism, offering potential advantages over existing treatments including faster onset of action and improved tolerability.
| Attribute | Details |
|---|---|
| Headquarters | New York, NY |
| Founded | 2011 |
| IPO | 2017 (NASDAQ: RLMD) |
| CEO | Dr. Sergio Traversa |
| Employees | ~50-100 |
| Focus | CNS therapeutics, NMDA modulation |
| Round | Year | Amount | Notes |
|---|---|---|---|
| Series A | 2012 | $15M | Initial development |
| Series B | 2014 | $25M | Pre-IPO funding |
| IPO | 2017 | $40M | NASDAQ: RLMD |
| Post-IPO | 2020-2024 | $50M+ | Clinical development |
REL-1017 (esmethadone) is the D-isomer of racemic methadone, designed to provide NMDA receptor antagonist activity without the traditional opioid effects associated with the racemate. This selectivity allows for potentially therapeutic effects on mood and cognition while minimizing abuse potential and respiratory depression[2].
| Attribute | Details |
|---|---|
| Indication | Major Depressive Disorder (primary), Alzheimer's depression (exploratory) |
| Mechanism | NMDA receptor antagonist + sigma-1 receptor agonist |
| Route | Oral |
| Stage | Phase 3 completed (MDD), Phase 2 ongoing |
| Status | Active development; NDA filing anticipated |
| Program | Indication | Stage | Status |
|---|---|---|---|
| REL-1017 | Major Depressive Disorder | Phase 3 | Completed; results positive |
| REL-1017 | Alzheimer's depression | Phase 2 | Recruiting |
| REL-102 | Chronic neuropathic pain | Phase 2 | Completed |
| REL-1017 | Parkinson's disease depression | Preclinical | Exploring |
REL-1017 acts as a selective NMDA receptor antagonist, similar in mechanism to ketamine but without the dissociative side effects. The NMDA receptor plays a critical role in synaptic plasticity, learning, and memory — processes that are dysregulated in both depression and neurodegenerative diseases. By modulating this receptor, REL-1017 may restore proper glutamatergic signaling[2:1].
The sigma-1 receptor is a chaperone protein located on the endoplasmic reticulum that regulates calcium homeostasis and mitochondrial function. Sigma-1 receptor agonism has been associated with neuroprotective effects, including:
These mechanisms are particularly relevant to Alzheimer's disease and other neurodegenerative conditions where mitochondrial dysfunction and oxidative stress play key pathogenic roles[3].
Phase 3 trials for REL-1017 in major depressive disorder demonstrated:
While Relmada's primary focus is major depressive disorder, the company's research has implications for neurodegenerative diseases:
Depression is common in Alzheimer's disease, affecting up to 40% of patients. REL-1017's dual mechanism (NMDA antagonism + sigma-1 agonism) may address both mood symptoms and potentially modify disease progression through neuroprotective pathways. Relmada has initiated Phase 2 studies specifically targeting this patient population.
Depression affects approximately 50% of Parkinson's disease patients and significantly impacts quality of life. The NMDA modulator approach may provide therapeutic benefits while addressing underlying neurochemical imbalances.
REL-1017 competes with:
REL-1017's advantage lies in its oral delivery, non-dissociative mechanism, and proprietary D-isomer formulation.